The FDA granted tentative approval to Mylan Pharmaceuticals’ Abbreviated New Drug Application for Fluoxetine capsules, a generic version of Eli Lilly’s Sarafem and Pulvules capsules, which had annual US sales of approximately $52 million for the 12 months ending June 30, 2006. Fluoxetine Capsules are indicated for the treatment of premenstrual dysphoric disorder (PMDD). They are the AB-rated